OraPharma Inc. (acquired by JNJ)

What OraPharma Inc. (acquired by JNJ) does

OraPharma is a specialty pharmaceutical company that develops and commercializes prescription products for oral health, operating as a division of Bausch Health US, LLC and headquartered in Bridgewater, New Jersey. Its commercial portfolio centers on two product lines: ARESTIN (minocycline HCl) Microspheres, 1mg, the only FDA-approved locally applied antibiotic used with scaling and root planing to reduce pocket depth in adult periodontitis patients (on the U.S. market since 2001), and the OSSIX portfolio of dental bone grafting and regeneration products (OSSIX BONE, OSSIX PLUS, OSSIX VOLUMAX, OSSIX GRAFT) distributed in the U.S. through a partnership with Datum Dental Ltd.

The company's go-to-market is a B2B specialty pharma model targeting dental professionals — periodontists, general dentists, and dental practices — through direct field sales, formal partnerships with over 35 dental service organizations (DSOs), and a long-running Student Access program operating in more than 250 dental hygiene schools since 2007. OraPharma supplements clinical product sales with professional education delivered through OraAcademy, including ARESTIN certification, and uses celebrity partnerships (e.g., Alex Rodriguez in May 2023) for consumer gum-disease awareness.

The business generates revenue through one-time prescription product sales of ARESTIN and OSSIX to dental professionals, with pricing not publicly disclosed and influenced by insurance coverage and regional factors. The company has historically been U.S.-focused but announced commercial expansion into Canada and Puerto Rico in February 2026 alongside the ARESTIN 25th anniversary milestone. Note: the original query references acquisition by JNJ, but current source data indicates OraPharma is a subsidiary of Bausch Health Companies Inc. (NYSE: BHC), not JNJ.

Name

OraPharma Inc. (acquired by JNJ)

Legal name

OraPharma, a division of Bausch Health US, LLC

Website

https://orapharma.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Short description

OraPharma is a specialty pharmaceutical division of Bausch Health that develops and commercializes ARESTIN (minocycline microspheres) and the OSSIX bone regeneration portfolio for dental professionals, periodontists, and dental service organizations treating adult periodontitis in the U.S., Canada, and Puerto Rico.

Ownership category

akta.pro rank

Product category

Dental Pharmaceuticals

NAICS

Dental Equipment and Supplies Manufacturing (339114)

SIC

Dental Equipment & Supplies (3843)

akta.pro primary industry

In-Office Preventive Antimicrobial Therapies (e.g., Chlorhexidine) (HLABAHAI)

akta.pro secondary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

Keywords

• Dental pharmaceuticals
• Periodontal treatment products
• Bone grafting materials
• Oral health therapeutics
• Professional dental education

Headquarters

HQ city

Bridgewater

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Dental Products: OraPharma generates revenue through the sale of prescription pharmaceutical products to dental professionals, including ARESTIN (minocycline HCl) Microspheres for periodontal treatment and OSSIX bone grafting products. Products are sold through direct sales to dental practices and via dental service organization partnerships.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

OraPharma develops and commercializes specialty pharmaceutical products for oral health, primarily the ARESTIN (minocycline HCl) Microspheres product for adjunctive treatment of adult periodontitis and the OSSIX portfolio of bone regeneration and grafting products. Products are sold directly to dental professionals (periodontists and general dentists), dental practices, and through partnerships with dental service organizations (DSOs).

Product overview

OraPharma is a dental products company specializing in oral health solutions. The portfolio consists of two main product lines: Arestin® (minocycline HCl) Microspheres, an FDA-approved locally applied antibiotic for adult periodontitis treatment used with scaling and root planing, and the OSSIX® product portfolio (bone regeneration products) developed in partnership with Datum Dental Ltd. The company operates through dental service organizations and provides professional education resources for dental professionals.

Differentiator

Problem solved

Functional benefit

Brands

• Arestin: ARESTIN (minocycline HCl) Microspheres, 1mg - the only FDA-approved locally applied antibiotic used with scaling and root planing to reduce pocket depth in adult periodontitis patients.
• OSSIX
• OraAcademy

Products and services

• ARESTIN (minocycline HCl) Microspheres, 1 mg FDA-approved locally applied antibiotic used with scaling and root planing to reduce pocket depth in adult periodontitis patients. The only FDA-approved locally applied antibiotic for this indication, with over two decades of clinical experience. Sold to dental professionals for in-office use.
• OSSIX Portfolio Portfolio of bone regeneration and dental tissue products including OSSIX BONE, OSSIX PLUS, OSSIX VOLUMAX, and OSSIX GRAFT. Distributed in the U.S. through OraPharma's partnership with Datum Dental Ltd. for dental bone reconstruction procedures.

Quantifiable outcome

• ARESTIN used with scaling and root planing reduces pocket depth in adult periodontitis patients
• +1 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Alex RodriguezminorGTM or Marketing Partner · 31 May 2023OraPharma partnered with Alex Rodriguez (former MLB player) to raise awareness about the importance of managing gum disease. This celebrity partnership was announced on May 31, 2023, as part of OraPharma's consumer awareness marketing efforts.
• Datum Dental Ltd. (Datum Biotech, Ltd.)coreTechnology or IntegrationOraPharma maintains a partnership with Datum Dental Ltd. for the OSSIX product portfolio. OSSIX products are bone grafting and regeneration materials for dental procedures. The partnership enables OraPharma to distribute Datum Dental's OSSIX branded products in the U.S. market.
• Dental Service Organizations (35+ DSOs)coreChannel Partner/ Reseller/ DistributorOraPharma partners with over 35 dental service organizations nationwide to support dental practices by ensuring access to oral health products. DSOs serve as channel partners distributing OraPharma products to their affiliated dental practice network.
• Academic Institutions and Professional AssociationscoreStrategic or Co-development PartnerOraPharma collaborates with leading academic institutions and professional associations to benefit dental hygiene students and professionals. The company provides professional education resources and clinical training through these partnerships.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Colgate-Palmolive (Oral Care): Colgate-Palmolive is the leading consumer oral-care company and also serves dental professionals with Colgate Professional and periodontal prescription product lines. It addresses the same gum-disease category (prevention and treatment) but through a primarily consumer-and-professional consumables model rather than prescription pharma.
• Henry Schein: Henry Schein is the largest dental distributor in North America, providing practice supplies, equipment, and specialty products (including periodontics and regenerative) to dental practices and DSOs. It is an indirect competitor as a channel through which OraPharma-like products reach end-users.
• Patterson Companies: Patterson is a major dental and animal health distributor serving dental practices, DSOs, and specialists with supplies, equipment, and regenerative products. It competes with OraPharma indirectly through the distribution and supply of competing periodontal and regenerative products.
• Envista Holdings: Envista (parent of Nobel Biocare, KaVo Kerr, Ormco) is a diversified dental products platform spanning implants, orthodontics, and consumables. It overlaps with OraPharma in dental specialty consumables and the periodontist channel while operating a much broader product portfolio.
• Solventum (formerly 3M Health Care / 3M Oral Care): Solventum's oral care division supplies preventive dental products, restoratives, and orthodontic appliances to dental professionals globally. It competes broadly with OraPharma in the dental professional channel and overlaps in preventive and treatment consumables.

Direct peers

• Dentsply Sirona: Dentsply Sirona is one of the largest dental equipment, instruments, and consumables manufacturers serving dental professionals globally. It competes with OraPharma in dental specialty products (periodontics, endodontics, implants), reaching the same periodontist and DSO customers with overlapping clinical-use categories.
• Geistlich Pharma: Geistlich is the established leader in dental bone regeneration (e.g., Bio-Oss, Bio-Gide), a direct competitor to OraPharma's OSSIX bone graft portfolio. Both sell regenerative biomaterials to periodontists and dental specialists for the same bone augmentation and implant procedures.
• Straumann Group: Straumann is a global leader in dental implants and regenerative materials (including bone graft substitutes), competing most directly with the OSSIX portfolio. It sells to the same periodontist and oral-surgeon segment through specialty distribution channels, overlapping on bone regeneration procedures.

Emerging players

• Bicon Dental Implants: Bicon is a US dental implant and bone regenerative products company selling to periodontists and oral surgeons. It is a smaller emerging peer in the same specialty implant/regenerative market as OraPharma's OSSIX portfolio.
• Sunstar Americas: Sunstar markets the GUM brand of professional and consumer oral hygiene products (including antimicrobial rinses) and serves dental professionals with adjunctive periodontal products. It is an emerging competitor in the locally applied antimicrobial/preventive periodontal space adjacent to ARESTIN.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/orapharma-inc.

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OraPharma Inc. (acquired by JNJ)